Peregrine Pharmaceuticals  

(Public, NASDAQ:PPHM)   Watch this stock  
Find more results for PPHM
+0.020 (2.27%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.85 - 0.91
52 week 0.84 - 1.66
Open 0.90
Vol / Avg. 624,934.00/1.22M
Mkt cap 211.54M
P/E     -
Div/yield     -
EPS -0.30
Shares 229.70M
Beta 1.22
Inst. own 15%
Dec 16, 2015
Peregrine Pharmaceuticals Inc at ROTH Immuno-Oncology Corporate Access Day
Dec 10, 2015
Q2 2016 Peregrine Pharmaceuticals Inc Earnings Call - Webcast
Dec 10, 2015
Q2 2016 Peregrine Pharmaceuticals Inc Earnings Release
Dec 1, 2015
Peregrine Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Oct '15) 2015
Net profit margin -138.59% -188.04%
Operating margin -145.16% -188.56%
EBITD margin - -184.68%
Return on average assets -51.72% -53.57%
Return on average equity -93.80% -85.31%
Employees 211 -
CDP Score - -


14282 Franklin Ave
TUSTIN, CA 92780
United States - Map
+1-714-5086000 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Company’s therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.

Officers and directors

Carlton M. Johnson Jr. Independent Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Steven W. King President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul J. Lytle Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark R. Ziebell Vice President, General Counsel, Corporate Secretary
Age: 51
Bio & Compensation  - Reuters
Shelley P.M. Fussey Ph.D. Vice President - Intellectual Property
Age: 49
Bio & Compensation  - Reuters
Joseph S. Shan Vice President - Clinical & Regulatory Affairs
Age: 42
Bio & Compensation  - Reuters
David H. Pohl Independent Director
Age: 78
Bio & Compensation  - Reuters
Eric S. Swartz Independent Director
Age: 59
Bio & Compensation  - Reuters